In today’s recent session, 0.8 million shares of the Lexeo Therapeutics Inc (NASDAQ:LXEO) have been traded, and its beta is 1.63. Most recently the company’s share price was $3.94, and it changed around -$0.15 or -3.74% from the last close, which brings the market valuation of the company to $130.18M. LXEO at last check was trading at a discount to its 52-week high of $19.50, offering almost -394.92% off that amount. The share price’s 52-week low was $2.32, which indicates that the recent value has risen by an impressive 41.12% since then. We note from Lexeo Therapeutics Inc’s average daily trading volume that its 10-day average is 1.02 million shares, with the 3-month average coming to 454.79K.
Lexeo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended LXEO as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Lexeo Therapeutics Inc is expected to report earnings per share of -0.77 for the current quarter.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
Instantly LXEO has been showing red trend so far today with a performance of -3.74% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.49 on recent trading dayincreased the stock’s daily price by 12.25%. The company’s shares are currently down -40.17% year-to-date, but still up 33.01% over the last five days. On the other hand, Lexeo Therapeutics Inc (NASDAQ:LXEO) is 5.55% up in the 30-day period. We can see from the shorts that 2.43 million shares have been sold at a short interest cover period of 7.83 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 85.93% from its current value. Analyst projections state that LXEO is forecast to be at a low of $28 and a high of $28.
Lexeo Therapeutics Inc (LXEO) estimates and forecasts
Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -99.98%. Lexeo Therapeutics Inc earnings are expected to increase by -0.45% in 2025, but the outlook is positive 0.60% per year for the next five years.
Lexeo Therapeutics Inc (NASDAQ:LXEO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.25% of Lexeo Therapeutics Inc shares, and 106.47% of them are in the hands of institutional investors. The stock currently has a share float of 107.82%. Lexeo Therapeutics Inc stock is held by 120.0 institutions, with EVENTIDE ASSET MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 10.2089% of the shares, which is about 3.37 million shares worth $54.04 million.
JANUS HENDERSON GROUP PLC, with 9.5873% or 3.16 million shares worth $50.73 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Eventide Healthcare & Life Sciences Fund and Janus Henderson Global Life Sciences Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 1.23 shares worth $4.77 million, making up 3.73% of all outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held roughly 682.04 shares worth around $2.63 million, which represents about 2.06% of the total shares outstanding.
